Invitrogen has announced the creation of a new business unit that
aims to further integrate its presence within the cell therapy
market, as it aims to stamp its authority specifically in the cell
analysis tools market.
Invitrogen's first-quarter profits were nearly double those it
recorded in the first-quarter of 2007.The maker of kits used for
cloning enjoyed growth, driven by sharp increases in sales for drug
discovery and research.
After several years, Invitrogen and Agilent have at last settled
patent infringement court cases concerning tools used in
complementary DNA synthesis, polymerase chain reaction (PCR) and
other molecular biology applications.
Biotechnology firm Invitrogen has opened a new facility in New York
which can make its Advanced Granulation Technology (AGT) media
totally free of animal origin components while addressing key
bottlenecks in drug production.
Invitrogen has created three new business divisions in a move to
strengthen its position in the growing biotechnology industry and
drive growth through improving links between its product
development cycle and customer base.
Invitrogen has announced two additional acquisitions in the area of
nanotechnologcal tools for target and drug discovery, just as it
completes the earlier-announced purchase of Biosource
Invitrogen Corporation has acquired the publicly held life sciences
company BioSource International in a transaction totalling
approximately $130 million. This deal adds to Invitrogen's growing
collection of protein and primary...
Invitrogen and Agilent have entered into an agreement to co-market
an infectious agent detection system, which has shown to be
sensitive and specific for the identification of air and waterborne
Invitrogen announced it is to acquire Dynal Biotech, the molecular
separation and purification technology company. The deal will
provide Invitrogen with bead-based isolation technologies that
targets key medical research issues.
Invitrogen announced that it has obtained the licensed rights for
the development of protein microrrays, which contain more than 200
protein-based analytes, further increasing its intellectual
property position in the burgeoning microarray...
Invitrogen, which supplies reagents, services and software for the
life science market, has continued its acquisitive streak with the
announcement that it is paying $35 million (€27.5m) for a UK firm -
DNA Research Innovations - specialising...
US biotechnology company Invitrogen reported record second-quarter
revenue but warned that top-line growth for the rest of 2004 would
be less than expected, citing an increasingly competitive business
Invitrogen subsidiary Protometrix is gearing up to launch a
microarray containing nearly all the 6,200 or so proteins in the
proteome of the yeast Saccharomyces cerevisiae, a commonly
used organism in genomics research.
Invitrogen has made a cash offer for fellow US company Molecular
Probes in a deal which would give the firm a very strong presence
in fluorescence reagents for use in labelling molecules for
biological research and drug discovery.